A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma

Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) Performance status score 0-2
* Measurable or secretory multiple myeloma
* Relapse or progression of myeloma following prior systemic antineoplastic therapy
* Pretreatment clinical laboratory values meeting protocol-specified criteria
* Left ventricular ejection fraction rate within normal limits

Exclusion Criteria:

* Peripheral neuropathy or neuralgia \>=2, according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0
* Diagnosis of primary amyloidosis, plasma cell leukemia, or other similar conditions
* Diagnosis of Waldenstrom macroglobulinemia with protocol-specified immunoglobulin levels
* Prior histone-deacetylase inhibitor therapy - More than 3 prior lines of therapy
* Cardiac risk factors: unstable angina or myocardial infarction within the preceding 12 months, congestive heart failure (New York Heart Association Class II-IV), known presence of dilated, hypertrophic, or restrictive cardiomyopathy
* Any other cardiac abnormality that, in the opinion of the investigator, medical monitor, or consultant cardiologist, may place the patient at an unacceptably increased risk with study drug
* History of any of the following: sustained ventricular tachycardia, ventricular fibrillation, Torsades de Pointes, atrial fibrillation, cardiac arrest, Mobitz II second degree heart block, or third degree heart block - QTc at Screening \> 450 ms in males / \> 470 ms in females
* Family history of short QT syndrome, long QT syndrome
* Obligate use of a cardiac pacemaker - Use of medications that may cause Torsades de Pointes